JP6921821B2 - タンパク質のｐｅｇ化に用いるための添加物系 - Google Patents

タンパク質のｐｅｇ化に用いるための添加物系 Download PDF

Info

Publication number
JP6921821B2
JP6921821B2 JP2018526713A JP2018526713A JP6921821B2 JP 6921821 B2 JP6921821 B2 JP 6921821B2 JP 2018526713 A JP2018526713 A JP 2018526713A JP 2018526713 A JP2018526713 A JP 2018526713A JP 6921821 B2 JP6921821 B2 JP 6921821B2
Authority
JP
Japan
Prior art keywords
reaction
peg
protein
pegylation
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018526713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019503994A5 (enExample
JP2019503994A (ja
Inventor
マシュー・アール・ヒッキー
アントニオ・ラミレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019503994A publication Critical patent/JP2019503994A/ja
Publication of JP2019503994A5 publication Critical patent/JP2019503994A5/ja
Priority to JP2021123154A priority Critical patent/JP7257457B2/ja
Application granted granted Critical
Publication of JP6921821B2 publication Critical patent/JP6921821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018526713A 2015-11-23 2016-11-22 タンパク質のｐｅｇ化に用いるための添加物系 Active JP6921821B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021123154A JP7257457B2 (ja) 2015-11-23 2021-07-28 タンパク質のｐｅｇ化に用いるための添加物系

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562258644P 2015-11-23 2015-11-23
US62/258,644 2015-11-23
PCT/US2016/063313 WO2017091568A1 (en) 2015-11-23 2016-11-22 Additive systems for use in protein pegylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021123154A Division JP7257457B2 (ja) 2015-11-23 2021-07-28 タンパク質のｐｅｇ化に用いるための添加物系

Publications (3)

Publication Number Publication Date
JP2019503994A JP2019503994A (ja) 2019-02-14
JP2019503994A5 JP2019503994A5 (enExample) 2019-12-26
JP6921821B2 true JP6921821B2 (ja) 2021-08-18

Family

ID=57589163

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018526713A Active JP6921821B2 (ja) 2015-11-23 2016-11-22 タンパク質のｐｅｇ化に用いるための添加物系
JP2021123154A Active JP7257457B2 (ja) 2015-11-23 2021-07-28 タンパク質のｐｅｇ化に用いるための添加物系

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021123154A Active JP7257457B2 (ja) 2015-11-23 2021-07-28 タンパク質のｐｅｇ化に用いるための添加物系

Country Status (17)

Country Link
US (3) US10617765B2 (enExample)
EP (2) EP3789395B1 (enExample)
JP (2) JP6921821B2 (enExample)
KR (1) KR102688003B1 (enExample)
CN (2) CN108350025B (enExample)
CY (1) CY1123699T1 (enExample)
DK (1) DK3380487T3 (enExample)
ES (1) ES2827776T3 (enExample)
HR (1) HRP20201832T1 (enExample)
HU (1) HUE052634T2 (enExample)
LT (1) LT3380487T (enExample)
PL (1) PL3380487T3 (enExample)
PT (1) PT3380487T (enExample)
RS (1) RS61072B1 (enExample)
SI (1) SI3380487T1 (enExample)
SM (1) SMT202000649T1 (enExample)
WO (1) WO2017091568A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017091568A1 (en) * 2015-11-23 2017-06-01 Bristol-Myers Squibb Company Additive systems for use in protein pegylation
LT3849614T (lt) * 2018-09-11 2024-03-25 Ambrx, Inc. Interleukino-2 polipeptido konjugatai ir jų panaudojimas
CN111484551B (zh) * 2020-03-19 2022-02-11 北京翼方生物科技有限责任公司 一种聚乙二醇修饰的重组人碱性成纤维细胞生长因子

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
JP5460958B2 (ja) * 2004-03-17 2014-04-02 アンチキャンサー インコーポレーテッド タンパク質ポリエチレングリコール（ｐｅｇ）複合体形成を増大させる方法
TW200722521A (en) * 2005-06-01 2007-06-16 Alza Corp Novel bioconjugation reactions for acylating polyethylene glycol reagents
JP5508716B2 (ja) * 2005-11-08 2014-06-04 アンブルックス，インコーポレイテッド 非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
ES2385114T3 (es) * 2007-03-30 2012-07-18 Ambrx, Inc. Polipéptidos de FGF-21 modificados y sus usos
CA2899448C (en) 2013-01-30 2021-10-26 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
HK1222122A1 (zh) 2013-04-22 2017-06-23 Avelas Biosciences, Inc. 选择性药物递送组合物及使用方法
SG11201702824UA (en) 2014-10-24 2017-05-30 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
WO2017091568A1 (en) * 2015-11-23 2017-06-01 Bristol-Myers Squibb Company Additive systems for use in protein pegylation

Also Published As

Publication number Publication date
US20220160883A1 (en) 2022-05-26
US10617765B2 (en) 2020-04-14
JP2021176890A (ja) 2021-11-11
US20200276319A1 (en) 2020-09-03
EP3789395B1 (en) 2025-08-27
CY1123699T1 (el) 2022-03-24
HRP20201832T1 (hr) 2021-01-08
ES2827776T3 (es) 2021-05-24
US11213589B2 (en) 2022-01-04
DK3380487T3 (da) 2020-12-07
CN115819494A (zh) 2023-03-21
SI3380487T1 (sl) 2020-11-30
CN108350025B (zh) 2023-02-21
EP3789395A1 (en) 2021-03-10
US20190351065A1 (en) 2019-11-21
RS61072B1 (sr) 2020-12-31
JP2019503994A (ja) 2019-02-14
CN108350025A (zh) 2018-07-31
KR20180081610A (ko) 2018-07-16
JP7257457B2 (ja) 2023-04-13
SMT202000649T1 (it) 2021-01-05
LT3380487T (lt) 2020-12-28
EP3380487A1 (en) 2018-10-03
KR102688003B1 (ko) 2024-07-23
PT3380487T (pt) 2020-10-29
HUE052634T2 (hu) 2021-05-28
PL3380487T3 (pl) 2020-12-28
WO2017091568A8 (en) 2018-01-04
WO2017091568A1 (en) 2017-06-01
EP3380487B1 (en) 2020-09-02

Similar Documents

Publication Publication Date Title
JP2021176890A (ja) タンパク質のｐｅｇ化に用いるための添加物系
Špačková et al. Fast and Cost‐Efficient 17O‐Isotopic Labeling of Carboxylic Groups in Biomolecules: From Free Amino Acids to Peptide Chains
Guthrie et al. Ketoxime peptide ligations: oxidative couplings of alkoxyamines to N-aryl peptides
JP2023512634A (ja) Ｃ末端の選択的標識のための化合物および方法
US20220372141A1 (en) Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
Damer et al. Rh‐Catalyzed Hydroamination of Allenes: Asymmetric N‐Allylation of Amino Acids and Peptides
Arrigoni et al. Morpholine Prevents the Formation of Aspartimide from β-allyl ester aspartic acid during Fmoc Cleavage in SPPS of Stapled Peptides
Byun et al. Preparation of polymer-bound pyrazolone active esters for combinatorial chemistry
Mandavkar et al. Identification and Synthesis of Process-Related Impurities in Lisdexamfetamine Dimesylate
US8357820B2 (en) Process for producing N-protected amino acid
KR101692992B1 (ko) 고리형 펩타이드의 사전 활성화 합성방법 및 이에 따라 합성된 고리형 펩타이드
Easton et al. N-Methylation of carbamate derivatives of α-amino acids
US20240319146A1 (en) Analysis method for peptide bound to carrier for liquid phase peptide synthesis
Sornay et al. Investigating Multicomponent Approaches for the Site-Selective Conjugation of Native Proteins
Zangana Synthesis of Amino Acids from Chiral NiII Schiff Base Complexes for Novel Stapled Peptides
Scheck Development of a Biomimetic Transamination Reaction for the N-terminal Labeling of Proteins and Peptides
Vaidyanathan 4 The SUTENT Story
Méret Development of an efficient and flexible method for the solid-phase synthesisof n-hydroxypolyamine derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210728

R150 Certificate of patent or registration of utility model

Ref document number: 6921821

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250